EARLYDIAGNOSTICS

Company Overview

EarlyDx, founded as a spinout from UCLA and Stanford, is developing and commercializing liquid biopsy technologies for early cancer detection and health monitoring.

EarlyDx’s CancerLocator is a liquid biopsy test that can detect cancer at its earliest stages and provide a tissue of origin for the tumor. The test is based on cfDNA methylation technology. A proprietary algorithm, CancerDetector, models the joint methylation patterns of multiple adjacent CpG sites to identify tumor-derived cfDNA at the level of individual reads. CancerDetector amplifies and aggregates tumor signals across the genome, enabling detection of tumor cfDNA in proportions as low as 0.1%.

In October 2023, EarlyDx received an NIH U01 grant for “Multi-cancer early detection using cell-free DNA methylome analysis” in conjunction with UCLA and MD Anderson. EarlyDx will join the NIH Liquid Biopsy Consortium as a result of this award.

Company's Business Segments

• Genomics Technologies : The company provides accurate, affordable, and non-invasive liquid biopsy tests for early cancer detection and precision medicine.